Rocco Verducci

Novartis Buys Protez For Super Anti-Biotic Defense

Eben,

The carbapenem class of antibiotics has demonstrated excellent efficacy against a wide range of bacteria and make it an very good choice for presumptive therapy for infection.

Novartis has actually limited their financial exposure by structuring a deal that only has them paying $100M up front with the rest to be paid only if the antibiotic meets certain developmental milestones. Additionally, Novartis's scientists have no doubt done their due diligence with respect to the initial payment and the expectations are probably very high for this antibiotic.

Ciao